Researchers at LSTM and Imperial College London have designed drugs which could help combat any potential new flu pandemic, by targeting the receptors of the cells by which the virus gains entry to the human body.
In a paper published today(link is external) in the Journal of Immunology the team, led by LSTM’s Professor Richard Pleass, show that by engineering a part of an antibody they can target the viral proteins that allow flu to mutate and become so deadly to humans.
Last year marked the centenary of the 1918 influenza pandemic that claimed nearly 100 million lives worldwide, thus becoming the deadliest disease outbreak in recorded history. Global annual influenza outbreaks account for 300,000-650,000 respiratory deaths, mostly in children and the elderly.
Professor Pleass explained: “Influenza vaccines have limited public health impact during pandemics, and current influenza vaccines are less efficacious than vaccines for many other infectious diseases. This is because influenza viruses that circulate in human and animal populations mutate two key viral surface proteins, haemagglutinin (HA) and neuraminidase (NA), thus allowing them to escape from protective antibodies produced through natural infection or vaccination”
Both HA and NA target a sugar called sialic acid, that is found in abundance on the receptors of cells lining the mammalian respiratory tract, which the virus uses to gain entry into the body. The sialic acid-binding contacts on HA and NA do not mutate readily, otherwise the virus would not be able to infect human cells.
The team has engineered antibody Fc fragments with enhanced sialic acid that target these conserved parts of both HA and NA, binding influenza viruses and thus blocking their interactions with human cells.
By targeting sialic acid, these engineered biologicals may also be useful in the control of other pathogens, such as group B streptococci, Streptococcus pneumoniae, Mycoplasma genitalium, and Newcastle Disease Virus.
“Better anti-influenza therapeutics are urgently needed.” Continued Professor Pleass: “The transfer of antibodies from people recovering from influenza during the 1918 and 2009 pandemics reduced mortality from influenza by 50% and 26% respectively. However, to be useful, these antibody medicines (also called FLU-IVIG) need to be manufactured in advance of future epidemics, which is obviously problematic as there may be modest or little neutralising activity against newly emerging strains. Therefore, combinations of existing medicines, including FLU-IVIG, with sialic acid blockers could increase their efficacy while future-proofing against the next pandemic.”
Professor Sara Marshall, Head of Clinical and Physiological Sciences at the Wellcome Trust, who provided funding for this work, said: “This is a fascinating project, and one which could have really far-reaching impact not only for influenza but as a platform technology to develop new medicines for many other diseases that are currently treated by antibodies.”
The technology described is available for licensing.
The Latest on: Anti-influenza drugs
via Google News
The Latest on: Anti-influenza drugs
- Fujifilm stock rises as Japan considers Avigan for COVID-19 treatmenton February 25, 2020 at 11:45 am
“On February 22, one of the medical centers started administration of the anti-influenza drug Avigan.” The Japanese company said it is considering increasing production of Avigan. The medicine has a ...
- Japan’s plan to recommend virus drug sees Fujifilm shares soaron February 24, 2020 at 8:34 pm
Japan markets were closed on Monday for a public holiday. Fujifilm is considering boosting output of the anti-influenza drug Avigan (favipiravir) after it was asked to by the Japanese government, ...
- Japan’s Plan to Recommend Drug for Coronavirus Sees FujiFilm Shares Soaron February 24, 2020 at 8:10 pm
Fujifilm Holdings Corp. rose as much as 8.8% following Japanese Health Minister Katsunobu Kato’s comments over the weekend on the country’s plans to recommend its Avigan drug to treat coronavirus.
- Japan Starts Using Antiflu Drug Avigan for Coronaviruson February 22, 2020 at 6:23 pm
Tokyo, Feb. 23 (Jiji Press)--A Japanese medical institution started on Saturday using Avigan, an anti-influenza medication ... according to Kato. The drug was used for treatment as part of an ...
- Recommendations for the Prevention and Treatment of Influenza Using Antiviral Drugs Based on Cost–Effectivenesson February 22, 2020 at 4:00 pm
Four antiviral drugs are available for the prevention and treatment of influenza infections ... the primary method for disease prevention, anti-influenza drugs can be used as an adjunct to ...
- Japan weighs using anti-flu drug Avigan to treat Covid-19 patientson February 22, 2020 at 3:34 am
TOKYO: Japanese Health Minister Katsunobu Kato said on Saturday (Feb 22) that the country is mulling using Avigan, an anti-influenza medication to treat patients of the Covid-19 (coronavirus) outbreak ...
- Gov't considers using anti-flu drug Avigan to treat coronaviruson February 22, 2020 at 1:26 am
Avigan, developed by Fujifilm Toyama Chemical Co, has been manufactured and stocked in Japan as an anti-influenza drug, but it is hoped that it can help treat other diseases, including Ebola, as well ...
- Japan considers using anti-influenza drug Avigan to treat novel Coronavius infectionson February 22, 2020 at 12:58 am
an anti-influenza medication, said Katsunobu Kato, the country's health minister on Saturday. Noting that there is standardised treatment for the disease currently, he suggested that the drug which is ...
- Japan might approve anti-flu drug Avigan to treat coronavirus patientson February 21, 2020 at 10:58 pm
Japan is considering using Avigan, an anti-influenza medication developed by a unit of Fujifilm ... noting that there is no established treatment for COVID-19 yet. The drug is also known as ...
- Japan mulls using anti-flu drug Avigan to treat coronaviruson February 21, 2020 at 5:11 pm
TOKYO (Kyodo) -- Japan is considering using Avigan, an anti-influenza medication developed by a Fujifilm Holdings Corp. group company, to treat patients of the new coronavirus, health minister ...
via Bing News